CTOs on the Move


 
OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

OncoResponse raised $22.5M on 03/09/2017
OncoResponse raised $40M on 09/11/2018

Similar Companies

MindMaze

MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.

ProteomTech Inc

ProteomTech Inc is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accent Therapeutics

Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kezar Life Sciences

Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.